MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study to evaluate several intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Major trial goals have been To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis people, though among the exploratory ... https://kameronrxchk.blog-kids.com/31102694/considerations-to-know-about-sifalimumab